Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Y3M | ISIN: NO0010779341 | Ticker-Symbol: 9Y8
Frankfurt
27.06.25 | 09:59
0,152 Euro
+4,82 % +0,007
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOINVENT ASA Chart 1 Jahr
5-Tage-Chart
ONCOINVENT ASA 5-Tage-Chart

Aktuelle News zur ONCOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Oncoinvent ASA: Oncoinvent: Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases1
18.06.Oncoinvent AS: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin in Patients with Colorectal Peritoneal Metastases212Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO...
► Artikel lesen
18.06.Oncoinvent ASA: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases2
14.05.Oncoinvent ASA: Minutes from the annual general meeting 2025-
30.04.Oncoinvent Q1 2025 slides: promising cancer therapy data, solid cash position1
ONCOINVENT Aktie jetzt für 0€ handeln
30.04.Oncoinvent ASA: Notice of Annual General Meeting-
28.04.Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update185OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English...
► Artikel lesen
28.04.Oncoinvent ASA: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression3
28.04.Oncoinvent AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression235OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month...
► Artikel lesen
28.04.ONCOINVENT AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression3
28.04.Oncoinvent ASA: Financial calendar1
25.03.Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients1
05.03.Oncoinvent ASA: Mandatory notification of trade-
27.02.Oncoinvent ASA: Fourth Quarter 2024 Update and Results1
27.02.Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients1
26.02.Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference253Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference...
► Artikel lesen
20.02.Oncoinvent ASA: Invitation to Result Presentation Q4 2024408OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events: Thursday...
► Artikel lesen
19.02.Oncoinvent ASA to present at various conferences-
18.02.Oncoinvent ASA: Registration of new share capital-
06.02.Oncoinvent ASA: Last day of the subscription period in the subsequent offering1
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1